/
JANX
$15.33+$0.38 (+2.58%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$911.1M
61M shares
52-week range
$12.12 – $35.34
14% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.34%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-9.63
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3.6M | $8.6M | $8.1M | $10.6M | $10.0M |
| Cost of revenue | $6.0K | $13.0K | $26.2M | $841.0K | $2.0M | $2.1M | $2.0M |
| Gross profit | −$6.0K | −$13.0K | −$22.6M | $7.8M | $6.1M | $8.5M | $8.0M |
| Gross margin | — | — | -621.4% | 90.2% | 75.8% | 80.5% | 79.7% |
| R&D | $3.0M | $3.0M | $26.2M | $53.4M | $54.9M | $68.4M | $125.9M |
| Operating income | −$3.8M | −$4.8M | −$32.9M | −$67.1M | −$73.0M | −$98.8M | −$157.7M |
| EBITDA | −$3.8M | −$6.6M | −$32.6M | −$62.2M | −$56.3M | −$66.9M | −$111.6M |
| Net income | −$4.2M | −$6.8M | −$32.7M | −$63.1M | −$58.3M | −$69.0M | −$113.6M |
| Net margin | — | — | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (diluted) | -0.10 | -0.16 | -0.79 | -1.52 | -1.32 | -1.28 | -1.83 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $32M | $-1.70 | $-2.52–$-0.99 | 13 |
| 2027 | $7M | $-2.68 | $-3.26–$-1.76 | 12 |
| 2028 | $17M | $-3.24 | $-4.88–$-1.95 | 13 |
| 2029 | $76M | $-3.47 | $-8.09–$-0.15 | 11 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Janux Therapeutics, Inc. Common Stock
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
www.januxrx.com- Employees
- 108
- IPO / List date
- Jun 11, 2021
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds JANX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in JANX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded JANX yet.
